Cochrane · systematic review · CD011741
Growth factors for angiogenesis in peripheral arterial disease
Gorenoi, V, Brehm, MU, Koch, A, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 4 · 80%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Growth factors versus placebo or no therapy for the treatment of peripheral arterial disease
Population: people who have been diagnosed with peripheral arterial disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Major limb amputation ( Growth factors vs placebo or no therapy | OR 0.99 [0.71, 1.38] | 10 studies · 1075 participants | Moderate Downgraded: risk of bias, imprecision |
Any limb amputation ( Growth factors vs placebo or no therapy | OR 0.56 [0.31, 0.99] | 6 studies · 415 participants | Low Downgraded: risk of bias |
Death ( Growth factors vs placebo or no therapy | OR 0.99 [0.69, 1.41] | 12 studies · 1371 participants | Moderate Downgraded: risk of bias, imprecision |
Serious adverse events ( Growth factors vs placebo or no therapy | OR 1.09 [0.79, 1.5] | 13 studies · 1411 participants | Moderate Downgraded: risk of bias, imprecision |
Any adverse event ( Growth factors vs placebo or no therapy | OR 1.1 [0.73, 1.64] | 13 studies · 1411 participants | Moderate Downgraded: risk of bias, imprecision |